The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.
The main objective of this study is to assess efficacy of the product on skin translucency after 84 days of product compared to a placebo. The study will also evaluate the effect of the product on different skin parameters (radiance, firmness, elasticity, skin barrier function, skin pH, blood flow) with different instruments. The quality of life and the improvement of skin properties will also be collected with questionnaires completed by the subjects. Finally, the safety of this product will be assessed by collecting all adverse events that might occur during the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
108
4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin
4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin
4 capsules per day, each capsule containing 400 mg of maltodextrin
EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.
Guangzhou, China
Change from baseline on skin translucency parameter Alpha at 84 days
The skin translucency parameter Alpha is measured with translucency meter
Time frame: From enrollment to 84 days of supplementation
Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days
The skin translucency parameters Alpha, Area and Kis are measured with translucency meter
Time frame: From enrollment to 28 days of supplementation
Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days
Skin complexion radiance measured with Colorface®
Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on pigment spot at 14, 28, 56 and 84 days
Pigment spot measured with Colorface®
Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days
Skin firmness, elasticity and fatigability measured with Cutometer®
Time frame: From enrollment to 28 and 84 days of supplementation
Change from baseline on Trans Epidermal Water Loss at 28 and 84 days
Trans Epidermal Water Loss measured with Tewameter®
Time frame: From enrollment to 28 and 84 days of supplementation
Product safety
Safety assessed by the collection of adverse events and concomitant treatments throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From enrolment to 84 days